Human clinical trial of NIH-developed dengue vaccine begins

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and is undergoing clinical study at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

View full post on National Institutes of Health (NIH) News Releases

Leave a Reply

Your email address will not be published. Required fields are marked *